http://www.azilect.com/azilect.pdf.
10. Zhang Z, Wang J, Chen S, et al. Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study. Transl Neurodegener. 2018 Dec 6;7:32.
11. Elgart A, Rabinovich-Guilatt L, Eyal E, Gross A, Spiegelstein O. Pharmacokinetics and safety of single and multiple doses of rasagiline in healthy Japanese and caucasian subjects. Basic Clin Pharmacol Toxicol. 2019 Mar;124(3):273-284.
12. Hattori N, Takeda A, Takeda S, Nishimura A, Kato M, Mochizuki H, Nagai M, Takahashi R. Efficacy and safety of adjunctive rasagiline in Japanese Parkinson’s disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study. Parkinsonism Relat Disord.2018 Aug;53:21-27.
13. Chen, X., Zhao, Q., Jiang, J.et al. Pharmacokinetics of Rasagiline in Healthy Adult Chinese Volunteers with Various Genotypes: A Single-Center, Open-Label, Multiple-Dose Study. Clin Drug Investig. 2016;36:369–376.
14. Pintér, D., Lajtos, J., Janszky, J. and Kovács, N. Clinical Experience with Generic Rasagiline (Ralago®) in Patients with Parkinson’s Disease: An Open-Label, Multicenter, Observational Study. Advances in Parkinson’s Disease. 2019; 8:18-34.
15.US Food and Drug Administration. Guidance for industry: food-effect bioavailability and fed bioequivalence studies, 2002. Available at:https://www.fda.gov/media/70945/download (accessed 22.04.2020).
16.National Medical Products Administration. Technical guidelines for the study of human bioequivalence in the pharmacokinetics of chemical generic drugs, 2016. Available at:http://www.nmpa.gov.cn/WS04/CL2138/300138.html. (accessed 22.04.2020).
17. Kang SP, Ratain MJ. Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin Cancer Res. 2010 Sep 1;16(17):4446-51.
18.Fleisher D, Li C, Zhou Y, Pao L, Karim. A Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications. ClinPharmacokinet. 1999;36:233–254
19.Welling PG. Effects of food on drug absorption. Annu Rev Nutr. 1996;16:383–415.
20. Van Rijswick YGJ, Quesada MJ, Van Os SHG. Bioequivalence between generic rasagiline (As Tartrate) and rasagiline (As Mesylate). J Bioequiv. 2016;2(1):104.
21. US Food and Drug Administration. Guidance for industry bioavailability and bioequivalence studies submitted in NDAs or INDs-general considerations[EB /OL]2014. Available at: